Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

European shares jumped on Wednesday after Ukraine accepted the U.S.' proposal for a 30-day ceasefire with Russia, while ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.

Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...